论文部分内容阅读
目的观察2型糖尿病患者加用罗格列酮治疗后对胰高血糖素样肽-1(GLP-1)的影响。方法用胰岛素和二甲双胍联合治疗的2型糖尿病患者共74例,随机分为观察组38例和对照组36例,观察组加用罗格列酮(4 mg/d)治疗6个月后,采用酶联免疫吸附法(ELISA)检测空腹胰高血糖素样肽-1(GLP-1),氧化酶法检测空腹血糖(FPG)和早餐后2 h血糖(2hPG)及总胆固醇(TC)和甘油三酯(TG),柱层析法检测糖化血红蛋白(HbA1c),化学发光法测定空腹胰岛素(FINS)水平。观察两组干预前后FPG、FINS、2hPG、HbA1c、TC、TG的变化及干预后GLP-1的变化。结果 两组患者年龄、糖尿病病程、体质量指数、性别差异无统计学意义(P>0.05),具有可比性;观察组经罗格列酮干预6个月后,患者血清中的FPG、2hPG、FINS、HbA1c、TC、TG水平均较治疗前显著下降(P<0.05),空腹血清GLP-1水平较对照组升高(P<0.05)。结论 罗格列酮可有效的降低2型糖尿病患者的血糖及HbA1c,改善胰岛素抵抗,促进空腹GLP-1分泌。
Objective To investigate the effects of rosiglitazone on glucagon-like peptide-1 (GLP-1) in type 2 diabetic patients. Methods A total of 74 patients with type 2 diabetes mellitus treated with insulin and metformin were randomly divided into observation group (38 cases) and control group (36 cases). In the observation group, rosiglitazone (4 mg / d) Fasting plasma glucagon-like peptide-1 (GLP-1) was detected by enzyme linked immunosorbent assay (ELISA), fasting plasma glucose (FPG) and 2hPG, TC and glycerol Triglyceride (TG), HbA1c by column chromatography, and fasting insulin (FINS) by chemiluminescence. The changes of FPG, FINS, 2hPG, HbA1c, TC, TG before and after intervention and the changes of GLP-1 after intervention were observed. Results There was no significant difference in age, duration of diabetes, body mass index and sex between the two groups (P> 0.05). After 6 months’ intervention of rosiglitazone in observation group, FPG, 2hPG, The levels of FINS, HbA1c, TC and TG were significantly lower than those before treatment (P <0.05). The fasting serum GLP-1 level was higher than that of the control group (P <0.05). Conclusion Rosiglitazone can effectively reduce blood glucose and HbA1c, improve insulin resistance and promote fasting GLP-1 secretion in type 2 diabetic patients.